789 related articles for article (PubMed ID: 30569448)
1. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
2. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
Trinchet JC; Bourcier V; Chaffaut C; Ait Ahmed M; Allam S; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Buffet C; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Thiefin G; Hillaire S; Di Martino V; Nahon P; Chevret S;
Hepatology; 2015 Sep; 62(3):737-50. PubMed ID: 25678021
[TBL] [Abstract][Full Text] [Related]
3. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
Allaire M; Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; DI Martino V; Sutton A; Letouzé E; Audureau E; Roudot-Thoraval F;
Hepatology; 2018 Oct; 68(4):1245-1259. PubMed ID: 29663511
[TBL] [Abstract][Full Text] [Related]
4. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.
Loko MA; Salmon D; Carrieri P; Winnock M; Mora M; Merchadou L; Gillet S; Pambrun E; Delaune J; Valantin MA; Poizot-Martin I; Neau D; Bonnard P; Rosenthal E; Barange K; Morlat P; Lacombe K; Gervais A; Rouges F; See AB; Lascoux-Combe C; Vittecoq D; Goujard C; Duvivier C; Spire B; Izopet J; Sogni P; Serfaty L; Benhamou Y; Bani-Sadr F; Dabis F;
BMC Infect Dis; 2010 Oct; 10():303. PubMed ID: 20969743
[TBL] [Abstract][Full Text] [Related]
5. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.
Quaranta MG; Ferrigno L; Monti M; Filomia R; Biliotti E; Iannone A; Migliorino G; Coco B; Morisco F; Vinci M; D'Ambrosio R; Chemello L; Massari M; Ieluzzi D; Russo FP; Blanc P; Verucchi G; Puoti M; Rumi MG; Barbaro F; Santantonio TA; Federico A; Chessa L; Gentile I; Zuin M; Parruti G; Morsica G; Kondili LA;
Hepatol Int; 2020 May; 14(3):362-372. PubMed ID: 32279177
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study.
Marcon PDS; Tovo CV; Kliemann DA; Fisch P; de Mattos AA
World J Gastroenterol; 2018 Feb; 24(5):613-622. PubMed ID: 29434450
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
Mussini C; Lorenzini P; Puoti M; Lichtner M; Lapadula G; Di Giambenedetto S; Antinori A; Madeddu G; Cozzi-Lepri A; d'Arminio Monforte A; De Luca A;
PLoS One; 2015; 10(12):e0140877. PubMed ID: 26640953
[TBL] [Abstract][Full Text] [Related]
8. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.
Salmon D; Bani-Sadr F; Loko MA; Stitou H; Gervais A; Durant J; Rosenthal E; Quertainmont Y; Barange K; Vittecoq D; Shoai-Tehrani M; Alvarez M; Winnock M; Trinchet JC; Dabis F; Sogni P
J Hepatol; 2012 Apr; 56(4):862-8. PubMed ID: 22173166
[TBL] [Abstract][Full Text] [Related]
10. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
11. Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
Lewin M; Gelu-Simeon M; Ostos M; Boufassa F; Sobesky R; Teicher E; Meyer L; Fontaine H; Salmon-Céron D; Samuel D; Seror O; Trinchet JC; Duclos-Vallée JC
Radiology; 2015 Nov; 277(2):443-53. PubMed ID: 25961631
[TBL] [Abstract][Full Text] [Related]
12. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V; Kallan MJ; Tate JP; Localio AR; Lim JK; Goetz MB; Klein MB; Rimland D; Rodriguez-Barradas MC; Butt AA; Gibert CL; Brown ST; Park L; Dubrow R; Reddy KR; Kostman JR; Strom BL; Justice AC
Ann Intern Med; 2014 Mar; 160(6):369-79. PubMed ID: 24723077
[TBL] [Abstract][Full Text] [Related]
13. Incidence of hepatocellular carcinoma in hepatitis C cirrhotic patients with and without HIV infection: a cohort study, 1999-2011.
Di Benedetto N; Peralta M; Alvarez E; Schroder MT; Estepo C; Paz S; Fainboim H
Ann Hepatol; 2013 Jan-2014 Feb; 13(1):38-44. PubMed ID: 24378264
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
15. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
16. Liver decompensation in HIV/Hepatitis B coinfection in the combination antiretroviral therapy era does not seem increased compared to hepatitis B mono-infection.
Lieveld FI; Smit C; Richter C; van Erpecum KJ; Spanier BWM; Gisolf EH; Vrolijk JM; Siersema PD; Hoepelman AIM; Reiss P; Arends JE
Liver Int; 2019 Mar; 39(3):470-483. PubMed ID: 30411848
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; José Ríos-Villegas M; Márquez-Solero M; Omar M; Macías J; Camacho A; Pérez-Pérez M; Gómez-Mateos J; Rivero A; Antonio Pineda J;
Hepatology; 2012 Jul; 56(1):228-38. PubMed ID: 22278746
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration.
Zampino R; Pisaturo MA; Cirillo G; Marrone A; Macera M; Rinaldi L; Stanzione M; Durante-Mangoni E; Gentile I; Sagnelli E; Signoriello G; Miraglia Del Giudice E; Adinolfi LE; Coppola N
Ann Hepatol; 2015; 14(1):75-82. PubMed ID: 25536644
[TBL] [Abstract][Full Text] [Related]
19. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
[TBL] [Abstract][Full Text] [Related]
20. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
